"It's true we create an intellectually stimulating environment for our scientists. But I truly believe our unique culture revolves around continually asking ourselves, 'If I was a patient, what would I want to see in my products?'" Dr. Steve Petteway Senior Vice President - Research & Development The Scientist profiles Dr. Steve Petteway (PDF)

At Talecris, our award-winning research and development teams focus their efforts on the discovery of new protein therapies, the development of advanced manufacturing technologies, and innovative virus removal and inactivation techniques.

Additional development projects with existing products represent expanded indications, more efficient production processes, and alternate routes of administration, including aerosol and subcutaneous injections.

Pathogen safety scientists at Talecris Biotherapeutics have been pioneers in developing processes that remove or inactivate viral and other infectious particles, including the pathogenic prion associated with variant Creutzfeldt-Jakob disease. Over the past several years, Talecris has led the way with research demonstrating removal or inactivation of viruses, such as West Nile virus, vaccinia (the virus used in smallpox vaccinations), and human immunodeficiency virus (HIV) from plasma-derived therapies.

Among our R&D achievements, Talecris is the only fractionator approved by the FDA and licensed to do in-house nucleic acid testing for hepatitis C, hepatitis B, and human immunodeficiency virus in pools of human plasma prior to entering the manufacturing process.

Another example of our innovative work is Plasmin. Plasmin represents a new class of direct-acting thrombolytics that may provide the first localized, nonsystemic treatment of blood clots. Talecris is actively pursuing development of Plasmin using both plasma-derived and recombinant technologies.

Complementing our internal R&D efforts, Talecris also sponsors external research grant programs that advance scientific knowledge. These include grants made to organizations such as the Alpha-1 Foundation, or programs such as Talecris Talents and the Partnership Fund, supporting research efforts of clinicians, scientists, and early career investigators.

You need the Adobe® Reader® installed on your computer to view PDFs. You can download a copy of the Adobe Reader by clicking the link below.

Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.